In extracts from purified ELVs have been obtained following ultracentrifugation of UAs from age-matched groups of control, kind 1 and kind two EC patients (ten patients/group). The good quality of ELVs was monitored by nanoparticle tracking analysis and immunoblot. To profile protein abundance across various groups, we create a super-SILAC approach where ELV proteins from three diverse EC cell lines grown in heavy amino acids have been combined with ELV protein extracts of every patient. Proteins have been separated by SDS-PAGE and 10 gel-isolated bands per patient have been digested with trypsin and analysed by mass spectrometry. From 2138 proteins identified, we generated a list of 54 protein candidates that had been further validated by selected reaction monitoring (SRM) in an independent cohort of 107 patients such as sort 1 EC (n = 45) EC, kind two EC (n = 21) and controls (n = 41). A total of 86 one of a kind peptides matching the proteins of interest were monitored. Protein quantitation was performed making use of a QTRAP 5500 Sciex instrument. Outcomes: Our targeted mass spectrometry method confirmed that ELVs from uterine aspirates contain proteins which can discriminate among cancer individuals and healthy people, and may classify EC inside the diverse subtypes. A 2-protein signature, composed of Agrin and CD81, achieved an AUC = 0.935 for EC diagnosis. In addition, we also report a new protein signature, combining CLD6, and RAB8A, that can differentiate kind 1 versus form 2 EC (AUC = 0.932). This study has essential implications in early detection of EC and in patient stratification. Summary/conclusion: A targeted mass spectrometry method defines protein signatures for endometrial cancer Carboxypeptidase D Proteins manufacturer diagnosis and stratification of patients in ELVs isolated from uterine aspirates.PT05.Proteome analysis of glioma-derived extracellular vesicles isolated from neurosurgical aspirates offer markers for disease stage and progression Susannah Hallal1; Ben Russell1; Brindha Shivalingam2; Michael Buckland2; Kimberley KaufmanThe University of Sydney, Sydney, Australia; 2Royal Prince Alfred Hospital, Sydney, AustraliaPT05.Protein signatures in exosome-like vesicles of uterine aspirates improve the diagnosis and stratification of endometrial cancer patients Irene Campoy1; Cristian Moiola1; Marc Hirschfeld2; Jasmin Asberger2; Silvia Cabrera3; Xavier Matias-Guiu4; Jaume Reventos1; Eduard Sabid; Antonio Gil Moreno6; Pierre Thibault7; Eva Colas1 Group of Biomedical Study in Gynecology, Vall Hebron Institute of Research (VHIR), CIBERONC, Barcelona, Spain; 2Department of Obstetrics and Gynecology, University Healthcare Center, Serine/Threonine Kinase 3 Proteins supplier Albert-Ludwigs-University, Freiburg, Germany, Freiburg, Germany; 3Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain, Barcelona, Spain; 4Pathological Oncology Group and Pathology Division, University Hospital Arnau de Vilanova, and University Hospital Bellvitge, IRBLLEIDA and Idibell, University of Lleida. CIBERONC, Barcelona, Spain; 5 Proteomics Unit, Universitat Pompeu Fabra (UPF) and Centre de RegulaciGen ica (CRG), Barcelona, Spain; 6Department of Gynecological Oncology, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain, Barcelona, Spain; 7Proteomics and Bioanalytical Mass Spectrometry research unit. IRIC (Institute of Study in Immunology and Cancer), Montreal, CanadaBackground: Endometrial cancer (EC) accounts for much more than 10,000 deaths per year within the US alone. EC is divided in to the much more typical and significantly less aggress.